EP4727976A2 - Anticorps spécifiques de la protéine a liée à la chaîne du cmh de classe i (mica) et leurs utilisations - Google Patents

Anticorps spécifiques de la protéine a liée à la chaîne du cmh de classe i (mica) et leurs utilisations

Info

Publication number
EP4727976A2
EP4727976A2 EP24824246.3A EP24824246A EP4727976A2 EP 4727976 A2 EP4727976 A2 EP 4727976A2 EP 24824246 A EP24824246 A EP 24824246A EP 4727976 A2 EP4727976 A2 EP 4727976A2
Authority
EP
European Patent Office
Prior art keywords
seq
acid sequence
amino acid
antibody
lcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24824246.3A
Other languages
German (de)
English (en)
Inventor
Manoj Kumar Sabnani
Laura T. GRAY
Jennifer Watkins
Zhiqian Lucy LIU
Hemanta Baruah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aakha Biologics Inc
Original Assignee
Aakha Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aakha Biologics Inc filed Critical Aakha Biologics Inc
Publication of EP4727976A2 publication Critical patent/EP4727976A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente divulgation concerne le traitement du cancer. En particulier, la présente invention concerne de nouveaux anticorps thérapeutiques qui ciblent la protéine A liée à la chaîne du CMH de classe I (MICA) d'une manière qui réduit la capacité d'une cellule tumorale d'échapper à la clairance immunitaire à médiation par le récepteur NKG2D (groupe des cellules tueuses 2D).
EP24824246.3A 2023-06-15 2024-06-14 Anticorps spécifiques de la protéine a liée à la chaîne du cmh de classe i (mica) et leurs utilisations Pending EP4727976A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508360P 2023-06-15 2023-06-15
PCT/US2024/034063 WO2024259273A2 (fr) 2023-06-15 2024-06-14 Anticorps spécifiques de la protéine a liée à la chaîne du cmh de classe i (mica) et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4727976A2 true EP4727976A2 (fr) 2026-04-22

Family

ID=93852761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24824246.3A Pending EP4727976A2 (fr) 2023-06-15 2024-06-14 Anticorps spécifiques de la protéine a liée à la chaîne du cmh de classe i (mica) et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4727976A2 (fr)
KR (1) KR20260026071A (fr)
CN (1) CN121532429A (fr)
AU (1) AU2024304442A1 (fr)
IL (1) IL325269A (fr)
JO (1) JOP20250308A1 (fr)
WO (1) WO2024259273A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154585A1 (fr) * 2015-03-26 2016-09-29 Charles Sentman Fragments de liaison à l'antigène anti-mica, molécules hybrides, cellules exprimant ceux-ci et procédés d'utilisation
WO2022170126A2 (fr) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Composés spécifiques à la protéine s du coronavirus et leurs utilisations

Also Published As

Publication number Publication date
AU2024304442A1 (en) 2026-01-15
WO2024259273A2 (fr) 2024-12-19
CN121532429A (zh) 2026-02-13
JOP20250308A1 (ar) 2025-12-14
IL325269A (en) 2026-02-01
WO2024259273A3 (fr) 2025-04-24
KR20260026071A (ko) 2026-02-25

Similar Documents

Publication Publication Date Title
CN112020515B (zh) 用于肿瘤特异性细胞清除的抗-cd25
EP4159757A1 (fr) Molécule de liaison à la protéine de spicule du sars-cov-2 et son utilisation
JP2022101682A (ja) ＨＩＶ ｇｐ１２０を標的化する抗体および使用方法
KR102907326B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
EP4347655A1 (fr) Anticorps anti-ccr8 et leurs utilisations
EP2997042B1 (fr) Anticorps anti-cxcl1, cxcl7 et cxcl8 et leurs applications
CN110997723A (zh) Cd38调节抗体
WO2019084307A1 (fr) Anticorps anti-mertk et leurs procédés d'utilisation
JP2022547850A (ja) 抗ｔｉｇｉｔ免疫阻害剤及び応用
TW202115123A (zh) 一種抗ｐｄ－ｌ１抗原結合蛋白及其應用
WO2019089753A2 (fr) Anticorps cd137 et antagonistes pd-1 et leurs utilisations
US20250346653A1 (en) Bispecific antibodies and method of treating ocular disease
CN110461875A (zh) 结合light的抗原结合分子
JP2022536913A (ja) Ｐｄ－１に対する抗体およびその使用方法
TW202321458A (zh) 新穎抗體組合及其用途
WO2025108184A1 (fr) Anticorps anti-tmem176b, composition pharmaceutique et utilisation
AU2024304442A1 (en) Mhc class i chain-related protein a (mica)-specific antibodies and uses thereof
WO2019199896A1 (fr) Anticorps agonistes contre le cd137 humain dans le cancer exprimant le cmh i
US20240415884A1 (en) Molecules that bind to cd276 polypeptides
RU2841957C1 (ru) Сконструированные антитела против il-2
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
WO2024227154A1 (fr) Anticorps spécifiques de composant 3 du complément (c3) et leurs utilisations
JP2024544386A (ja) Ｐｄ－ｌ１抗原結合タンパク質及びその使用
JP2024539893A (ja) 感染性障害を治療する方法で使用するためのブチロフィリン（ｂｔｎ）３ａ活性化抗体
TW202430569A (zh) 靶向sirpa與密連蛋白18.2的雙特異性分子

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251208

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR